Bicocca Open Archive

Logo unimib boa
RIZZARI, CARMELO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.151
AS - Asia 6.203
EU - Europa 4.266
SA - Sud America 951
AF - Africa 131
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 8
Totale 20.724
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.918
SG - Singapore 2.304
VN - Vietnam 1.131
CN - Cina 1.098
HK - Hong Kong 874
RU - Federazione Russa 792
DE - Germania 742
BR - Brasile 721
IT - Italia 684
IE - Irlanda 487
SE - Svezia 483
UA - Ucraina 219
FR - Francia 199
GB - Regno Unito 169
IN - India 149
CA - Canada 131
FI - Finlandia 130
BD - Bangladesh 89
AR - Argentina 82
AT - Austria 79
KR - Corea 75
ID - Indonesia 73
TR - Turchia 62
IQ - Iraq 56
MX - Messico 53
NL - Olanda 53
CO - Colombia 48
ES - Italia 48
PL - Polonia 47
ZA - Sudafrica 45
PH - Filippine 41
PK - Pakistan 39
SA - Arabia Saudita 37
JP - Giappone 35
EC - Ecuador 31
VE - Venezuela 21
DK - Danimarca 20
EG - Egitto 18
UZ - Uzbekistan 18
CZ - Repubblica Ceca 17
MA - Marocco 15
AE - Emirati Arabi Uniti 14
BE - Belgio 14
CL - Cile 14
KE - Kenya 14
MY - Malesia 14
AU - Australia 13
HN - Honduras 13
JO - Giordania 13
CH - Svizzera 12
PY - Paraguay 12
GR - Grecia 10
BG - Bulgaria 9
IL - Israele 9
PE - Perù 9
RO - Romania 9
BO - Bolivia 8
BZ - Belize 8
TH - Thailandia 8
AL - Albania 7
IR - Iran 7
LB - Libano 7
NO - Norvegia 7
TN - Tunisia 7
ET - Etiopia 6
KZ - Kazakistan 6
PA - Panama 6
CI - Costa d'Avorio 5
DO - Repubblica Dominicana 5
LT - Lituania 5
NP - Nepal 5
OM - Oman 5
PT - Portogallo 5
RS - Serbia 5
AO - Angola 4
AZ - Azerbaigian 4
BW - Botswana 4
CR - Costa Rica 4
DZ - Algeria 4
EU - Europa 4
UY - Uruguay 4
BA - Bosnia-Erzegovina 3
BY - Bielorussia 3
DM - Dominica 3
LK - Sri Lanka 3
LV - Lettonia 3
MN - Mongolia 3
PS - Palestinian Territory 3
QA - Qatar 3
SY - Repubblica araba siriana 3
BB - Barbados 2
BH - Bahrain 2
EE - Estonia 2
GA - Gabon 2
GE - Georgia 2
GT - Guatemala 2
LA - Repubblica Popolare Democratica del Laos 2
NI - Nicaragua 2
SN - Senegal 2
TT - Trinidad e Tobago 2
Totale 20.699
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.254
Singapore 1.228
Ashburn 864
Hong Kong 855
San Jose 648
Frankfurt am Main 570
Fairfield 484
Woodbridge 477
Dublin 460
Chandler 387
Ho Chi Minh City 328
Hanoi 309
Houston 287
New York 275
Wilmington 261
Beijing 211
Los Angeles 209
Santa Clara 203
Jacksonville 192
Dallas 189
Chicago 185
Cambridge 183
Seattle 179
Princeton 176
Milan 159
The Dalles 149
Hefei 137
Dearborn 110
Lauterbourg 100
Buffalo 90
Lawrence 88
Moscow 81
São Paulo 81
Altamura 75
Seoul 68
Vienna 66
Council Bluffs 59
Munich 56
San Diego 53
Shanghai 52
Helsinki 51
Nanjing 49
Jakarta 46
Haiphong 41
Da Nang 40
Orem 40
London 39
Warsaw 37
Guangzhou 33
Lachine 31
Montreal 31
Boardman 30
Nuremberg 30
Rio de Janeiro 30
Tokyo 30
Toronto 30
Turku 29
Denver 28
Salt Lake City 27
Baghdad 26
Rome 26
Chennai 23
Phoenix 23
Andover 22
Atlanta 21
Biên Hòa 21
Bogotá 21
Brooklyn 21
Thái Nguyên 21
Dhaka 20
Brasília 19
Johannesburg 19
Mexico City 19
Stockholm 19
Amsterdam 18
Lissone 18
Naples 18
Falls Church 17
Hải Dương 17
Lappeenranta 17
Quận Bình Thạnh 17
Can Tho 16
Jeddah 16
Tampa 16
Tashkent 16
Turin 16
Boston 15
Buenos Aires 15
Changsha 15
Lahore 15
Shenyang 15
Belo Horizonte 14
Bắc Ninh 14
Elk Grove Village 14
Ha Long 14
Hangzhou 14
Ninh Bình 14
Ottawa 14
Paris 14
Hebei 13
Totale 13.233
Salva come PNG Salva come JPEG
Nome #
Four Additional Doses of PEG-L-Asparaginase during the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study 517
First evidence of a paediatric patient with Cornelia de Lange syndrome with acute lymphoblastic leukaemia 450
Acute myeloid leukaemia niche regulates response to L-asparaginase 438
Italian expert consensus recommendations for the safe administration of high-dose methotrexate in children with cancer and for the use of glucarpidase to manage delayed methotrexate elimination and/or high-dose methotrexate-induced acute kidney injury 419
Combined CAR-T/HSCT approach in a patient with refractory acute lymphoblastic leukemia and cystic fibrosis 391
ActivinA: a new leukemia-promoting factor conferring migratory advantage to B-cell precursor-acute lymphoblastic leukemic cells 375
A novel EP300 mutation associated with Rubinstein-Taybi syndrome type 2 presenting as combined immunodeficiency 352
Children with cancer in the time of COVID-19: An 8-week report from the six pediatric onco-hematology centers in Lombardia, Italy 336
Reduced-Intensity delayed intensification in standard-Risk pediatric acute lymphoblastic leukemia defined by undetectable minimal residual disease: Results of an international randomized trial (AIEOP-BFM ALL 2000) 331
Lessons after the early management of the COVID-19 outbreak in a pediatric transplant and hemato-oncology center embedded within a COVID-19 dedicated hospital in Lombardia, Italy. Estote parati 306
Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study 302
Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations 299
Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants 296
Constitutional and somatic deletions of the Williams-Beuren syndrome critical region in non-Hodgkin lymphoma 292
High EVI1 Expression due to NRIP1/EVI1 Fusion in Therapy-related Acute Myeloid Leukemia: Description of the First Pediatric Case 289
A novel homozygous disruptive PRF1 variant (K285Sfs*4) causes very early-onset of familial hemophagocytic lymphohystiocytosis type 2 285
Development of a quantitative-PCR method for specific FLT3/ITD monitoring in acute myeloid leukemia 279
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial 279
PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120 275
Predictive factors of relapse and survival in childhood acute myeloid leukemia: Role of minimal residual disease 271
Screening for Coagulopathy and Identification of Children With Acute Lymphoblastic Leukemia at a Higher Risk of Symptomatic Venous Thrombosis: An AIEOP Experience 268
Mucopolysaccharidosis-Plus Syndrome, a Rapidly Progressive Disease: Favorable Impact of a Very Prolonged Steroid Treatment on the Clinical Course in a Child 265
Acute myeloid leukemia in Baraitser–Winter cerebrofrontofacial syndrome 263
Eight-year national multicenter experience on the use of glucarpidase as effective rescue therapy for delayed methotrexate elimination after high-dose methotrexate cycles administered in children with hemato-oncological diseases 258
Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-lineage acute lymphoblastic leukemia 256
Combination antifungal therapy for invasive mold infections among pediatric patients with hematological malignancies: Data from a real-life case-series 250
Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Münster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study--a report from the Associazione Italiana Ematologia Oncologia Pediatrica 243
Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study 229
FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemia 228
Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: A retrospective analysis 227
Musculoskeletal manifestations of childhood cancer and differential diagnosis with juvenile idiopathic arthritis (ONCOREUM): a multicentre, cross-sectional study 225
Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica 223
Outcome of very late relapse in children with acute lymphoblastic leukemia 221
Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy 220
Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment 220
Prognostic value of nephromegaly at diagnosis of childhood acute lymphoblastic leukemia 219
Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10–14 years as compared with those aged 15–17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study 217
Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995 216
Hermansky-Pudlak syndrome type II and lethal hemophagocytic lymphohistiocytosis: Case description and review of the literature 216
First-Line Postremission Blinatumomab as Successful Toxicity-Sparing Strategy in a Boy with Cystic Fibrosis and Acute Lymphoblastic Leukemia 209
Osteonecrosis in paediatric acute lymphoblastic leukaemia: Incidence, risk factors, radiological patterns and evolution in a single-centre cohort 205
Prenatal origin of NUTM1 gene rearrangement in infant B-cell precursor acute lymphoblastic leukaemia 204
Williams syndrome and mature B-Leukemia: A random association? 203
FLT3-ITD in Children with Early T-cell Precursor (ETP) Acute Lymphoblastic Leukemia: Incidence and Potential Target for Monitoring Minimal Residual Disease (MRD) 198
Asparagine transport through SLC1A5/ASCT2 and SLC38A5/SNAT5 is essential for BCP‐ALL cell survival and a potential therapeutic target 197
Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia 193
Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study 188
Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia 181
Ischemic stroke in children treated for acute lymphoblastic leukemia: a retrospective study 180
Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica 179
Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia 178
A Case of T-cell Acute Lymphoblastic Leukemia Relapsed As Myeloid Acute Leukemia 178
Role of DNA index in childhood acute lymphoblastic leukemia treated with BFM based therapy: Long term results of the AIEOP-ALL 95 177
Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups 176
Correspondence: Osteonecrosis in childhood acute lymphoblastic leukemia: a retrospective cohort study of the Italian Association of Pediatric Haemato-Oncology (AIEOP) 175
Are genotypes of glutathione S-transferase superfamily a risk factor for childhood acute lymphoblastic leukemia? Results of an Italian case-control study 174
Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II 170
MTHFR 677C-->T mutation and neural-tube defects 169
ALL blasts drive primary mesenchymal stromal cells to increase asparagine availability during asparaginase treatment 167
Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL 162
Legionellosis in paediatrics [Legionellosi in pediatria] 162
Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia 161
Blinatumomab in Children and Adolescents with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: A Real-Life Multicenter Retrospective Study in Seven AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica) Centers 159
Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies 159
Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children with Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol 156
Genotypes of the glutathione S-transferase superfamily do not correlate with outcome of childhood acute lymphoblastic leukemia 156
Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial 153
Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia 152
Challenging Management of Severe Differentiation Syndrome in Pediatric Acute Promyelocytic Leukemia Treated with ATRA/ATO 146
Hypersensitivity Reactions to Native E. coli L-asparaginase in Children with Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction 146
Impact of Antibodies Against Polyethylene Glycol on the Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukaemia: A Population Pharmacokinetic Approach 144
Global effort to evacuate Ukrainian children with cancer and blood disorders who have been affected by war 143
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study 140
Pharmacological and clinical monitoring in children with acute lymphoblastic leukemia treated with a biogeneric PEG-l-asparaginase product 139
A boy with Burkitt lymphoma associated with Noonan syndrome due to a mutation in RAF1 138
Favorable Outcome of Children with Acute Megakaryoblastic Leukemia Treated with the AIEOP AML 2002/01 Protocol 137
Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL 135
Road Traffic Pollution and Childhood Leukemia: A Nationwide Case-control Study in Italy 131
Biological therapies in monogenic autoinflammatory diseases: Long-term efficacy and safety 129
Collaborative efforts driving progress in pediatric acute myeloid leukemia 128
NUP214–ABL1 fusion in childhood T-ALL 127
Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph+ acute leukemias 124
Pharmacokinetics and Pharmacodynamics of Conventional-Dose vs Triple-Dose Oseltamivir in Severely Immunocompromised Children with Influenza 123
Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia 115
Nationwide central diagnosis review for childhood solid tumors: From concept to realization of an Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) integrated project 114
Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol 107
Phase I/Phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia 104
Emapalumab in children with primary hemophagocytic lymphohistiocytosis 100
Effect of Blinatumomab vs Chemotherapy on Event-Free Survival among Children with High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial 100
A three-miRNA-based expression signature at diagnosis can predict occurrence of relapse in children with t(8;21) RUNX1-RUNX1T1 acute myeloid leukaemia 99
Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data 98
Outcome of children with acute myeloid leukaemia (AML) experiencing primary induction failure in the AIEOP AML 2002/01 clinical trial 97
A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia 95
Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation 95
Prognostic significance of chromosomal abnormalities at relapse in children with relapsed acute myeloid leukemia: A retrospective cohort study of the Relapsed AML 2001/01 Study 95
A phase 2 study of nilotinib in pediatric patients with CML: Long-term update on growth retardation and safety 94
Pharmacokinetics of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia or acute lymphoblastic leukemia 93
Asparaginase pharmacokinetics and implications of therapeutic drug monitoring 92
Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium 92
Human Fibrinogen Concentrate and Fresh Frozen Plasma in the Management of Severe Acquired Hypofibrinogenemia in Children with Acute Lymphoblastic Leukemia: Results of a Retrospective Survey 92
Totale 20.079
Salva come PNG Salva come JPEG
Categoria #
all - tutte 74.674
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 74.674
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021204 0 0 0 0 0 0 0 0 0 0 97 107
2021/20221.311 85 99 105 164 141 135 53 67 106 81 71 204
2022/20231.712 247 528 95 149 112 278 18 82 117 16 44 26
2023/20241.355 83 33 58 69 168 353 275 32 117 22 18 127
2024/20253.880 182 509 210 183 307 94 171 82 462 567 374 739
2025/20268.633 1.099 590 696 959 972 842 1.475 450 635 769 146 0
Totale 21.304